Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem - Wikidata - awgldk - TriplyDB

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

http://www.wikidata.org/entity/Q42111612

about

Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus Control of the Staphylococcus aureus toxic shock tst promoter by the global regulator SarA.Site-specific mutation of Staphylococcus aureus VraS reveals a crucial role for the VraR-VraS sensor in the emergence of glycopeptide resistance.The sensor histidine kinase RgfC affects group B streptococcal virulence factor expression independent of its response regulator RgfA.Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus.Bacterial stress responses as determinants of antimicrobial resistance.Glycopeptide antibiotics: back to the future.Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.Antimicrobial heteroresistance: an emerging field in need of clarity.Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Targeting bactoprenol-coupled cell envelope precursors.Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus Epigallocatechin gallate induces upregulation of the two-component VraSR system by evoking a cell wall stress response in Staphylococcus aureus.Population Genomics of Reduced Vancomycin Susceptibility in Staphylococcus aureus.Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.In Vitro Tolerance of Drug-Naive Staphylococcus aureus Strain FDA209P to Vancomycin."Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.Reduced vancomycin susceptibility in porcine ST9 MRSA isolates.Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

P2860

Q28078930-B53D89EF-EB0A-4BAF-8BD8-BA62B5683B7E Q28478770-D662C993-9F9F-406B-9F30-2A899D0A6612 Q33696380-7D09349E-6E74-437D-967E-720D7ED9CA66 Q34057324-957F8310-5BC3-495C-A2C0-76BFC56F275B Q34291244-B201F9FF-A29D-44F1-A6C9-58B11B08E241 Q34737155-41BFF5FB-94DF-4ECB-8B5D-07751F1DBFCB Q35098179-E6FC36C1-63E8-4438-BBD5-F9093BDDECEA Q37575024-5896D718-95F2-46A1-A239-F8D7B50F311E Q38012391-DAB68054-C7B4-4836-8D80-4842F284B4B7 Q38239460-89C34448-58A4-407D-AF4F-BAC8770123B0 Q38282740-EE767115-1792-4C01-ABA7-CAD1BE8C5FB9 Q38310639-4EDE4897-526E-4CDA-932D-1615344DAFCD Q38843037-4971C805-52D7-44FB-8183-DADE07AA6278 Q38919751-9977C705-2DCA-4FAF-AA0B-581951581D08 Q40719288-C8A844B5-1F68-41BC-8CDA-211CF41DAEB8 Q41587609-DB71F4C9-190E-495A-BD5F-8A1A1F05B87D Q41776452-234FECC2-0F86-49A3-AC46-EF210D4A3B05 Q41855274-A0FAD67E-FDAC-4474-BF8E-7174AFB6AE14 Q41902616-60F7A7E6-D7AC-480A-A508-62B0FC274375 Q41921688-685659E0-EE08-44B9-9799-0E8BDC8DCBA3 Q42109713-27B1B93E-F9EC-4132-BA64-5C3271C0DEB9 Q42110109-953332DC-8C7A-4073-9117-933C1B0BC0D3 Q42110968-622F25A9-4D15-4BDA-A3C7-F12321BBCDF4 Q42358800-A8CD5FF6-642F-4260-BC7D-882AA1732C7A Q42905367-13357158-CFF6-4A04-A121-ACBEE99FC5B3 Q50420166-3A5605E5-11A2-48B1-94BC-7DB762E262D9

P2860

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

http://www.wikidata.org/entity/Q42111612

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@en

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@nl

type

label

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@en

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@nl

prefLabel

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@en

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@nl

P1433

Q42111612-7B46B5EE-8211-4B12-A661-D8AF7783721D

P1476

Q42111612-CBBDED0C-D161-41D9-A71B-493E6EA39BE2

P2093

Q42111612-0808956A-9333-4376-8C50-B8173C136266

Q42111612-193D4652-CFE7-4A58-B0B1-2E550E74A1FB

Q42111612-2D5C195E-05FA-40E1-A6C6-EA9CF3B9D5DB

Q42111612-9C86ABE0-B163-4662-9186-C6A7CEBACA14

P2860

Q42111612-0140061F-B242-4461-8D7D-80516A65CFE9

Q42111612-0253CC0E-CA53-44B7-B118-80033C859145

Q42111612-0DC2540B-D471-4B05-9F83-AC0BDB9FD8D7

Q42111612-0EB85892-275C-4B98-95BA-3242BB669E9A

Q42111612-0F6AB049-8CB8-42FD-807D-A5D74C7611F1

Q42111612-1870AA41-1324-43A4-A5CE-6C04B4A90AFA

Q42111612-1941C2C1-390A-42D2-A75E-7EB9FE45C2EB

Q42111612-19779D96-D761-4E46-B66E-4377216A6801

Q42111612-20A98842-3352-45FE-A915-86B297BE3286

Q42111612-2219B4E0-12F1-4092-A102-FDFC1DFE3E56

P304

Q42111612-7B708312-7640-4808-B55D-8B3351A105D8

P31

Q42111612-C68DC389-7CC0-413E-BABB-DC1C41353397

P356

Q42111612-D890F10B-68A4-46F3-BA8B-F92626AB2491

P407

Q42111612-208B0402-6180-41E3-8A3A-267FDFC3E895

P433

Q42111612-EC29EFA8-847E-455C-A567-5AD65D8122AF

P478

Q42111612-B2685279-DB06-45E3-82A1-181BBC066899

P577

Q42111612-DE7A09FD-D5C3-4150-A12A-4DFE748CC091

P698

Q42111612-261FCB47-A608-477F-8721-52604DFBB687

P932

Q42111612-426E9941-C00F-46C5-9E8B-12F7F42106AA

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem

@en

P2093

Hiroko Murakami-Kuroda

http://www.w3.org/2001/XMLSchema#string

Keiichi Hiramatsu

http://www.w3.org/2001/XMLSchema#string

Longzhu Cui

http://www.w3.org/2001/XMLSchema#string

Yuki Katayama

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus

Whole genome sequencing of meticillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania. .

Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin.

Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherap

Suppression of methicillin resistance in a mecA-containing pre-methicillin-resistant Staphylococcus aureus strain is caused by the mecI-mediated repression of PBP 2' production.

Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections.

P304

3190-3196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00834-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19451283

http://www.w3.org/2001/XMLSchema#string

P932

2715608

http://www.w3.org/2001/XMLSchema#string